BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 7, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2019

View Archived Issues

To sleep, perchance to clean: Sleep-inducing protein plays role in immunity

Read More

Stretching taxes CRISPR's abilities

Read More

Typhus vaccination broadly alters immune response

Read More

Sacituzumab govitecan demonstrates clinical activity in patients with metastatic urothelial cancer

Read More

Novel SIRT7 inhibitor demonstrates promising safety and efficacy in preclinical cancer models

Read More

Nektar Therapeutics presents preliminary data from phase Ib/II REVEAL study

Read More

Janssen reports phase I/II data for cetrelimab in patients with advanced cancers

Read More

Preliminary results from phase II study of lifileucel in metastatic melanoma

Read More

Adagene announces platform evaluation with Celgene

Read More

Verona reports part one data from phase II trial of DPI formulation of ensifentrine in COPD

Read More

Bristol-Myers Squibb presents lysophospholipid S1P1 receptor agonists

Read More

Arrowhead opens enrollment in phase I study of ARO-APOC3

Read More

Vyera Pharmaceuticals patents protozoal DHFR inhibitors

Read More

Single chain antibody against TDP-43 shows therapeutic potential in murine models of ALS/FTD

Read More

Vaccine targets generated by cell-free protein synthesis limit P. gingivalis-elicited oral bone loss

Read More

The Vanderbilt University discloses muscarinic M4 receptor antagonists

Read More

Rodin Therapeutics identifies HDAC inhibitors

Read More

Eli Lilly and Company synthesizes PDE1 inhibitors

Read More

Early trial data reported for anti-TIM-3 antibody LY-3321367 with anti-PD-L1 antibody LY-3300054

Read More

Funding to support exploration of TXA-127 for epidermolysis bullosa

Read More

Healx partners with Boston Children's Hospital to advance drug discovery in Barth syndrome

Read More

Lupus Therapeutics collaborates with Takeda on phase I trial of TAK-079 for SLE

Read More

OncBioMune initiates phase II study of Proscavax in localized prostate cancer

Read More

BirchBioMed initiates proof-of-concept study with FS-2 to reduce keloid scars

Read More

Apellis resumes enrollment in phase III geographic atrophy trials of APL-2

Read More

Axsome initiates phase III trial of AXS-07 for acute treatment of migraine

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing